Preferred Stock Purchase Rights
- Symbol
- No trading symbol declared
- Exchange
- NYSE
- Classification
- RIGHT
Current Report · Items 8.01, 9.01 · 8-K
INNOVATE Corp.
VATENYSEEQUITYCurrent
Other Events
Item 8.01 Other Events. On February 10, 2026, the Company issued a press release titled "Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)”. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.…
Recent company filings
- 10-Q filingNov 12, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 12, 2026
- Entry into a Material Definitive AgreementOct 9, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 5, 2026
- DEF 14C filingSep 3, 2026
Registered securities in this filing
INNOVATE CORP. · 8-K · Filed 2026-02-10
Common Stock, par value $0.001 per share
- Symbol
- VATE
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On February 10, 2026, the Company issued a press release titled "Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)”. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in a filing.